Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Bevacizumab
État du projet:
Terminé
Domaine thérapeutique:
Ovarian Cancer
Fabricant:
Hoffmann-La Roche Limited
Brand Name:
Avastin
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0047-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
25mg/mL
Tumour Type:
Gynécologique
Indications:
Ovarian Cancer
Funding Request:
In combination with paclitaxel and carboplatin for the front-line treatment of epithelial ovarian, fallopian tube or primary peritoneal cancer patients with high risk of relapse (stage III sub-optimally debulked, or stage III unresectable, or stage IV patients
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Demandée et refusée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016